Glucagon-like peptide-1 (GLP-1) is a natural, gut-derived hormone that is released after we eat. It has beneficial effects ...

By Dennis Thompson HealthDay ReporterFRIDAY, Aug. 8, 2025 (HealthDay News) — More than 1 in 10 Americans have used a GLP-1 ...

Doctors from only four medical specialties will be able to write prescriptions for injectable drugs that are used to treat ...

A new daily weight loss pill could be available soon – and a recent trial has shown that people taking the drug can shed kilos in weeks. Its release will offer people with obesity a new and convenient ...

Recently released results from a clinical trial on orforglipron show that the oral medication can cause impressive weight ...

ATTAIN-1 is the second trial this year to show positive results with once-daily orforglipron, with best results seen at the ...

Lilly's stock was tumbling as disappointing trial data for an oral weight-loss pill offset an upbeat earnings report and outlook. A previous report had an incorrect company name.

The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed ...

GLP-1 RAs are associated with a modestly increased risk for GERD and gallstone disease but not with GI and biliary complications.

Shares of Eli Lilly and Co. (LLY) tumbled 12.8% in premarket trading Thursday, toward its biggest one-day selloff in 26 years, after the drug giant disclosed late-stage trial data for its oral ...

He noted that the two types of medications have different strengths: SGLT2 inhibitors are particularly good at protecting ...